Prophylaxis for Patients on Mycophenolate Mofetil (MMF)
Patients on MMF should receive Pneumocystis jirovecii pneumonia (PCP) prophylaxis when receiving high-dose glucocorticoids (>15-30 mg prednisolone equivalent daily for >2-4 weeks), especially when combined with other immunosuppressants, and should be monitored closely for opportunistic infections including CMV, particularly in elderly patients and transplant recipients. 1, 2
Risk Assessment and Monitoring
MMF significantly increases susceptibility to bacterial, fungal, protozoal, and viral infections, including opportunistic infections that can lead to fatal outcomes 2. The FDA label explicitly warns that patients receiving MMF are at increased risk for:
- Polyomavirus-associated nephropathy (PVAN), particularly BK virus infection 2
- Progressive multifocal leukoencephalopathy (PML) from JC virus 2
- Cytomegalovirus (CMV) infections 2, 3
- Hepatitis B and C reactivation 2
- Severe neutropenia (ANC <0.5 x 10³/µL) in up to 2-3.6% of patients 2
PCP Prophylaxis Recommendations
When to Initiate
Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis should be strongly considered when: 1
- MMF is combined with glucocorticoids at doses >15-30 mg prednisolone equivalent daily for >2-4 weeks
- Additional immunosuppressants are used concurrently (particularly cyclophosphamide) 1
- Patient has risk factors: age >55 years, persistent lymphopenia, pre-existing lung disease, diabetes, or thrombocytopenia 1, 4
Dosing Regimens
First-line: TMP-SMX 480 mg (single-strength) daily or 960 mg three times weekly 1
Alternative if TMP-SMX not tolerated: 1
- Atovaquone
- Dapsone
- Nebulized pentamidine
Reduced doses (half-strength daily) may be equally effective with fewer adverse events, though approximately 20% of patients experience side effects (nausea, headache, rash) 1.
Specific Monitoring Requirements
CMV Surveillance
Highest risk patients require intensive monitoring: 2
- Transplant recipients who are CMV-seronegative receiving grafts from CMV-seropositive donors
- Elderly patients on chronic MMF therapy 3
- Therapeutic approaches to limiting CMV disease should be routinely provided 2
Neutropenia Monitoring
Monitor absolute neutrophil count regularly, particularly days 31-180 post-transplant: 2
- If ANC <1.3 x 10³/µL: interrupt or reduce MMF dosing
- If ANC <0.5 x 10³/µL: this represents severe neutropenia requiring immediate intervention
- Instruct patients to report immediately any signs of infection, bruising, or bleeding 2
Hepatitis Reactivation
Monitor infected patients for clinical and laboratory signs of active HBV or HCV infection 2
Drug Interactions Affecting Infection Risk
Avoid concurrent use of certain antibiotics that reduce MMF exposure through interference with enterohepatic recirculation: 5
- Oral antibiotics can severely decrease MPA exposure by diminishing gut bacteria β-glucuronidase activity
- This could result in rejection and requires close therapeutic drug monitoring 5
Specific antibiotics requiring caution: 2
- Sulfamethoxazole/trimethoprim (when used therapeutically, not prophylactically)
- Ciprofloxacin and norfloxacin
- Metronidazole
- Amoxicillin-clavulanate
Risk Stratification by Patient Population
Highest infection risk (requiring most aggressive prophylaxis): 4
- Age >55 years
- Diabetes mellitus present
- Central nervous system involvement
- Thrombocytopenia
- Longer duration of MMF use
- Higher MMF dosages
- Concurrent use with cyclophosphamide or multiple immunosuppressants
Specific infection types most commonly seen: 4
- Bacteremia/septicemia
- Urinary tract infection/pyelonephritis
- Herpes zoster
- Opportunistic infections (adjusted OR 2.13) 4
Clinical Pitfalls to Avoid
Do not delay prophylaxis initiation when combining MMF with high-dose glucocorticoids, as the risk-benefit ratio strongly favors prophylaxis 1.
Do not ignore neurological symptoms in immunosuppressed patients—consider PML in the differential and consult neurology as indicated 2.
Do not assume younger patients are protected—while elderly patients have higher risk, serious infections including CMV enteritis and EBV encephalitis can occur at any age 3.
Reduce immunosuppression when new or reactivated viral infections develop, while considering the risk to graft function 2.